Publicacions (149) Publicacions de MARINUS ANTONIUS JACOBUS HERMSEN

filter_list Specialties,%20Surgical

2025

  1. Sinonasal malignancy: ESMO–EURACAN Clinical Practice Guideline for diagnosis, treatment and follow-up ☆

    ESMO Open, Vol. 10, Núm. 2

2024

  1. Characterization of a Preclinical In Vitro Model Derived from a SMARCA4-Mutated Sinonasal Teratocarcinosarcoma

    Cells, Vol. 13, Núm. 1

  2. Experimental Models of Sinonasal Tumors for Preclinical Testing of Candidate Targeted Therapies

    Current Otorhinolaryngology Reports, Vol. 12, Núm. 1, pp. 1-10

  3. Next-generation sequencing reveals remarkable genetic stability in primary and corresponding recurrent intestinal-type sinonasal adenocarcinoma

    Head and Neck, Vol. 46, Núm. 8, pp. 2010-2019

  4. The European Network for Sinonasal Cancer Research (EUSICA) – A pan-European initiative targeting a group of orphan tumours

    European Journal of Cancer

  5. Whole exome sequencing of human papillomavirus-related multiphenotypic sinonasal carcinoma: a case report

    Frontiers in Oncology, Vol. 14

2023

  1. A Novel External Auditory Canal Squamous Cell Carcinoma Cell Line Sensitive to CDK4/6 Inhibition

    Otolaryngology - Head and Neck Surgery (United States), Vol. 168, Núm. 4, pp. 729-737

  2. EUSICA/COST IMMUNO-model workshop fostering collaboration to advance sinonasal cancer research: A meeting report

    Oral Oncology

  3. Optimal Combination of Neuroendocrine Markers for the Detection of High-Grade Neuroendocrine Tumors of the Sinonasal Tract and Lung

    Current Oncology Reports, Vol. 25, Núm. 1, pp. 1-10

  4. Signaling Pathways mTOR and ERK as Therapeutic Targets in Sinonasal Intestinal-Type Adenocarcinoma

    International Journal of Molecular Sciences, Vol. 24, Núm. 20

  5. Sinonasal Cancer: Improving Classification, Stratification and Therapeutic Options

    Cancers

  6. Sox2 and βIII-Tubulin as Biomarkers of Drug Resistance in Poorly Differentiated Sinonasal Carcinomas

    Journal of Personalized Medicine, Vol. 13, Núm. 10

  7. Translocations and Gene Fusions in Sinonasal Malignancies

    Current Oncology Reports, Vol. 25, Núm. 4, pp. 269-278

2022

  1. BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC

    European Journal of Cancer, Vol. 174, pp. S9-S10

  2. Biomarkers for Immunotherapy in Poorly Differentiated Sinonasal Tumors

    Biomedicines, Vol. 10, Núm. 9

  3. Clinical outcomes, Kadish-INSICA staging and therapeutic targeting of somatostatin receptor 2 in olfactory neuroblastoma

    European Journal of Cancer, Vol. 162, pp. 221-236

  4. DNA methylation-based classification of sinonasal tumors

    Nature Communications, Vol. 13, Núm. 1

  5. EGFR Exon 20 Insertion Mutations in Sinonasal Squamous Cell Carcinoma

    Cancers, Vol. 14, Núm. 2

  6. Exploiting the immunogenic potential of standard of care radiation or cisplatin therapy in preclinical models of HPV-associated malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 12

  7. International Multicenter Study of Clinical Outcomes of Sinonasal Melanoma Shows Survival Benefit for Patients Treated with Immune Checkpoint Inhibitors and Potential Improvements to the Current TNM Staging System

    Journal of Neurological Surgery, Part B: Skull Base, Vol. 84, Núm. 4, pp. 307-319